Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Partnerships and hiring data show AI companies are expanding beyond Nvidia chips

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Partnerships and hiring data show AI companies are expanding beyond Nvidia chips Date: 2025-11-04 02:25 Source: https://www.cbinsights.com/research/ai-companies-expand-beyond-nvidia/ <p><a href="https://www.cbinsights.com/company/nvidia">Nvidia</a> isn’t the only AI chip supplier in t…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than half of AWS Bedrock service now runs on Trainium AI chips

    80% confidence

  • AI demand is outpacing supply, creating opportunity to develop Trainium chip capacity

    80% confidence

  • Early signals in hiring and partnerships show the AI compute mix starting to split away from Nvidia dominance

    80% confidence

  • Anthropic is the notable exception to Nvidia's investments across leading AI companies

    80% confidence

  • As compute comes from multiple vendors, a larger market will emerge for software that abstracts chip differences

    80% confidence

  • TensorWave has deployed North America's largest AMD GPU cluster and is projecting $100M in ARR by year-end

    80% confidence

  • Switching from CUDA is a major barrier due to infrastructure, software ecosystem, and unknown learning costs

    80% confidence

  • Google opening TPU capacity at Anthropic scale signals both Anthropic's push for non-Nvidia supply and Google's bet that more buyers want alternatives

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Partnerships and hiring data show AI companies are expanding beyond Nvidia chips — Source | Via News | Via News